Revue des maladies respiratoires最新文献

{"title":"[Ruxolitinib, disseminated tuberculosis and primary myelofibrosis: A case study].","authors":"A Gérard, V Cauhape, J Courjon, D Viard, L Inchiappa, A Gaudart, F Vandenbos","doi":"10.1016/j.rmr.2025.06.005","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.06.005","url":null,"abstract":"<p><strong>Introduction: </strong>Ruxolitinib is a Janus kinase 2 inhibitor (JAK2i) used in patients with primary myelofibrosis. This treatment is a risk factor for bacterial and viral infections, and can reactivate latent infections, such as tuberculosis.</p><p><strong>Observation: </strong>We report the case of a 80-year-old patient hospitalized for disseminated tuberculosis. He had been treated for 28 months with ruxolitinib for JAK2^V617F-muted primary myelofibrosis. Pre-therapeutic screening for latent tuberculosis infection had not been performed. Sixteen months after starting ruxolitinib, bone, peritoneal, and lymph node lesions appeared. Finally, the diagnosis of disseminated tuberculosis was made 12 months after the first secondary lesions were observed. By then, tuberculosis had caused diffuse peritoneal involvement, staged lymph node involvement, pleuropulmonary, muscular, and especially multiple bone lesions with destruction of the 6th thoracic vertebra. A treatment with quadruple antituberculosis therapy led to slow improvement. Ruxolitinib was discontinued.</p><p><strong>Conclusion: </strong>Before initiating treatment with ruxolitinib, an immunological test for latent tuberculosis infection should be systematically performed, even in a country with a low tuberculosis incidence.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Epidemiology of childhood asthma in sub-Saharan Africa: A systematic literature review].","authors":"J G Mba Ndong, J A Bourobou Bourobou, E Ngoungou, S Aboughe Angone","doi":"10.1016/j.rmr.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.06.003","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is the most common chronic disease in children and adolescents worldwide. In sub-Saharan Africa, however, it is one of the most widely neglected diseases, and very few studies have focused on its occurrence during childhood. That said, two factors are known to contribute to its rapid increase. The first consists in the economic challenges related to its management, and the second concerns barriers to the implementation strategies that might reduce its global burden. With more than half of sub-Saharan Africa's population under the age of 15, childhood asthma is a critical issue that requires serious investigation.</p><p><strong>Method: </strong>Our approach was based on documentary search using the Google and Google Scholar databases. A list containing all relevant identified documents was created in the Zotero library management system for the purposes of online bibliographic sharing. To ensure (or at least reduce) duplicated efforts and so as facilitate potential collaboration, we registered our study in accordance with the PROSPERO systematic review protocol.</p><p><strong>Results: </strong>The results of this cross-sectional survey conclusively demonstrate that the prevalence of childhood asthma in this part of the continent is high and growing rapidly. It varies not only according to region or country, but also within the same territory. The highest levels south of the Sahara were found in East Africa, with prevalence exceeding the ISAAC protocol time trends by 23.1% in Tanzania and 21.3% in South Africa. There are many explanations for these elevated rates: (a) gaps in knowledge and perception of the disease, (b) insufficient control or deficient management, and (c) patients' divergent social levels.</p><p><strong>Conclusion: </strong>At present, the extent and severity of childhood asthma in sub-Saharan Africa is little known. In this context, the information collected in different publications could help to orient more adequate policies and to effectively develop good practices.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Should patients with respiratory failure and obesity be made to lose weight?]","authors":"A-L Borel, P Suzeau, J-C Borel","doi":"10.1016/j.rmr.2025.06.004","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.06.004","url":null,"abstract":"<p><p>Patients suffering from chronic respiratory failure may present with obesity, which can cause respiratory failure, particularly in cases of Obesity Hypoventilation Syndrome (OHS) or certain forms of asthma. It can also aggravate symptoms such as dyspnea. In this context, patients are often asked to change their lifestyle, or even to undergo bariatric surgery, the common objective being to help them lose weight. That said, a question may be raised: is weight loss always desirable? In the present review of relevant articles, we report on: (a) the current possibilities for achieving significant and lasting weight loss, (b) the arguments in favor of a weight loss strategy for patients with respiratory failure, and (c) the arguments suggesting a need for caution.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Thoracic electrical impedance tomography: Technical aspects and clinical applications].","authors":"N Mazellier, C Roussel, P-A Roger, G Jolly, C Caillard, C Girault, E Artaud-Macari","doi":"10.1016/j.rmr.2025.06.002","DOIUrl":"https://doi.org/10.1016/j.rmr.2025.06.002","url":null,"abstract":"<p><p>Thoracic Electrical Impedance Tomography (EIT) is a functional respiratory imaging technique first developed in the 1970s. It provides real-time functional information at the patient's bedside, without ionizing radiation. Its growing interest in clinical practice in recent years is the result of numerous technological advances, providing the practitioner with a tool for monitoring pulmonary ventilation, assessing the efficacy of therapeutic interventions, detecting complications such as pneumothorax, and obtaining data on pulmonary perfusion. Its use is gradually extending beyond the field of critical care, as it has become a promising tool for diagnosing and monitoring patients with chronic pulmonary disorders. This general review aims to raise physician awareness of this emerging technology, explaining its operating principles, the data it can collect and its main clinical applications, both inside and outside critical care units, thereby paving the way for new clinical management and research perspectives.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Sertraline-induced acute eosinophilic pneumonia: When a side effect becomes a clinical case].","authors":"L Brichard, C Stavart, J El Hayeck, C Dahlqvist, E Bodart","doi":"10.1016/j.rmr.2025.06.001","DOIUrl":"10.1016/j.rmr.2025.06.001","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic lung disease encompasses a group of diffuse pulmonary parenchymal diseases characterized by eosinophilic infiltration, either localized or associated with a systemic process. Acute eosinophilic pneumonia, a rare and severe form, is often confused with infectious pneumonia. Its main triggers include smoking, medication, and idiopathic causes. Cases reported in the literature link sertraline, a commonly prescribed antidepressant, to this condition.</p><p><strong>Case report: </strong>A 15-year-old female patient was admitted to hospital for febrile dyspnea, cough, chest pain, and hypoxemia. Her medical history included treatment with sertraline and smoking. Thoracic imaging revealed bilateral infiltrates, and bronchoalveolar lavage showed significantly increased eosinophils. Discontinuation of sertraline and initiation of corticosteroid therapy led to clinical improvement.</p><p><strong>Conclusions: </strong>This case highlights the importance of quickly identifying the rare adverse effects of antidepressants, particularly sertraline-induced acute eosinophilic pneumonia. Special attention is required when prescribing off-label this antidepressant to adolescents, especially in a context of rising mental health disorders in this population.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Use of fluticasone/umeclidinium/vilanterol in France: A population based study].","authors":"B Aguilaniu, J Cittee, L Watier, C Pribil, G Nachbaur, L Saïl, A Schmidt, A Panes, G Jebrak","doi":"10.1016/j.rmr.2025.05.003","DOIUrl":"10.1016/j.rmr.2025.05.003","url":null,"abstract":"<p><strong>Introduction: </strong>In France, the fixed combination fluticasone/umeclidinium/vilanterol (FF/UMEC/VI) is prescribed for the treatment of moderate to severe COPD in adults not adequately treated by LABA/LAMA or ICS/LABA dual therapy since 2018. The aim of our study was to describe the characteristics, prescribing trajectories and care pathways of patients prior to their first prescription of FF/UMEC/VI in France.</p><p><strong>Methods: </strong>A retrospective cohort study included all patients aged over 40years with a first prescription of FF/UMEC/VI between 2018 and 2019 in France using data from the SNDS database. Descriptive analysis were conducted in the 3years preceding initiation of this medication.</p><p><strong>Results: </strong>Of the 34,906 patients included, 92% had received a prescription for dual or triple therapy in the 3years prior to starting FF/UMEC/VI. The mean age at inclusion was 69, with a majority of men. A description of the care pathway showed that 68% of patients had moderate exacerbations and 25% had severe exacerbations leading to hospitalization.</p><p><strong>Conclusions: </strong>Our results demonstrate that triple inhaled therapy with FF/UMEC/VI is used in accordance with its marketing authorization in France in the vast majority of cases.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apport du lavage broncho-alvéolaire chez les patients intubés pour COVID-19","authors":"L.A. Pernaut ,&nbsp;F. Wallyn ,&nbsp;X. Dhalluin ,&nbsp;O. Ouennoure ,&nbsp;A. Rouzé ,&nbsp;C. Fournier","doi":"10.1016/j.rmr.2025.05.001","DOIUrl":"10.1016/j.rmr.2025.05.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Les infections pulmonaires compliquant la COVID-19 sont fréquentes. Le but de cette étude était de décrire les résultats des LBA de patients admis en réanimation pour COVID-19 sévère.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Étude observationnelle rétrospective incluant tous les LBA réalisés dans notre institution entre septembre 2020 et mai 2021 chez des patients intubés pour COVID-19.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Deux cent cinquante-huit LBA réalisés chez 195 patients ont été analysés. 12,9 % des patients avaient une infection bactérienne précoce, majoritairement en cas d’immunodépression (ID) et/ou de maladie respiratoire chronique (MRC). Une infection bactérienne acquise sous ventilation mécanique (IAVM) était diagnostiquée chez 29,6 % des patients. Une aspergillose pulmonaire associée à la COVID-19 (CAPA), selon les critères ECMM/ISHAM, était retrouvée chez 7,8 % des patients, d’autant plus en cas d’ID et/ou de MRC. Une PCR CMV et/ou HSV-1 était positive dans près d’un tiers des LBA, dont 43,8 % ont été traitées. L’analyse cytologique du LBA n’avait pas de conséquence thérapeutique évidente.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Les infections bactériennes pulmonaires précoces et les CAPA apparaissent plus fréquentes en cas d’ID et/ou de MRC, et doivent être envisagées chez ces patients. Les taux d’IAVM, plus fréquentes en cas de ventilation prolongée, ne diffèrent pas selon le terrain. L’apport de la virologie est incertain. L’examen cytologique du LBA semble avoir un impact thérapeutique limité.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Pulmonary infections complicating COVID-19 are common. The aim of this study was to describe the main findings regarding the impact of bronchoalveolar lavage (BAL) in severe COVID-19 patients in intensive care.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Retrospective observational study including all BALs performed in our institution between September 2020 and May 2021 in patients intubated for COVID-19.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Two hundred and fifty-eight BALs carried out in 195 patients were analyzed; 12.9% of patients had an early bacterial infection, mainly in contexts of immunodeficiency (ID) and/or chronic respiratory disease (CRD). A bacterial ventilation-acquired lower respiratory tract infection (VA-LRTI) was diagnosed in 29.6% of patients. COVID-19-associated pulmonary aspergillosis (CAPA), according to the ECMM/ISHAM criteria, was found in 7.8%, particularly in cases of ID and/or CRD. CMV and/or HSV-1 PCR were positive in nearly one-third of the BALs, of which 43.8% were treated. The histopathological results had no obvious therapeutic consequences.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Early bacterial pulmonary infections and CAPA appear more frequent in cases of ID and/or CRD, and should be investigated in the affected patients. Incidence of VA-LRTI, which is more frequent in cases of prolonged ventilation, does not differ based on the underlying ","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 6","pages":"Pages 298-306"},"PeriodicalIF":0.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence du tabagisme sur l’efficacité de l’immunothérapie dans les cancers pulmonaires de stade avancé","authors":"F. Biney ,&nbsp;É. Giroux-Leprieur ,&nbsp;C. Daniel ,&nbsp;P. Du Rusquec ,&nbsp;J.B. Auliac ,&nbsp;J.B. Assié ,&nbsp;S. Anane-abrous ,&nbsp;C. Chouaid","doi":"10.1016/j.rmr.2025.04.003","DOIUrl":"10.1016/j.rmr.2025.04.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Le cancer du poumon est la première cause de décès dans le monde. Il survient majoritairement chez les fumeurs, mais dans 25% des cas chez les non-fumeurs. Pour les stades métastatiques, l’utilisation de l’immunothérapie a permis une amélioration de la survie globale, mais avec une potentielle influence du statut tabagique sur leur efficacité. L’objectif de cette étude était d’analyser leur efficacité en première ligne de traitement pour les cancers pulmonaires avancés non à petites cellules (CBNPC) selon le statut tabagique des patients.</div></div><div><h3>Méthode</h3><div>L’étude rétrospective porte sur l’ensemble des patients avec un CBNPC stade IV traité par immunothérapie en première ligne, seule ou en association, entre 2018 et 2019 dans 3 centres d’Île de France. Le critère de jugement principal est la survie globale (SG) selon le statut tabagique. Le critère secondaire est la survie sans progression (SSP).</div></div><div><h3>Résultats</h3><div>L’analyse incluait 105 patients (66,7% d’hommes) dont 38% fumeurs actifs et 9,5% non-fumeurs, ayant dans 65,7% des cas un adénocarcinome. Les médianes de SG et de SSP étaient de 17, 23,2 et 24,9 mois et de 4,9, 7,6, et 4 mois pour les fumeurs, ex-fumeurs, non-fumeurs, sans différence significative.</div></div><div><h3>Conclusion</h3><div>Dans cette étude, le statut tabagique ne semblait pas modifier l’efficacité de l’immunothérapie. Des études sur une population plus importante seraient nécessaires.</div></div><div><h3>Introduction</h3><div>Lung cancer is the leading cause of death worldwide. It occurs mainly in smokers, but also in 25% of cases in non-smokers. As regards metastatic stages, while immunotherapy has led to improved overall survival, smoking status may potentially influence its effectiveness. The objective of this study was to analyze its effectiveness as first-line treatment for advanced non-small cell lung cancers (NSCLC) according to patient smoking status.</div></div><div><h3>Method</h3><div>This retrospective study covers all patients with stage IV NSCLC treated with first- line immunotherapy, alone or in combination, between January 2018 and 2019, in three Ile de France centers. The primary and secondary endpoints were, respectively, overall survival and progression-free survival, according to smoking status.</div></div><div><h3>Results</h3><div>The analysis included 105 patients (66.7% men) of whom 38% were active smokers and 9.5% non-smokers, with adenocarcinoma in 65.7% of cases. Median OS and PFS were 17, 23.2, and 24.9 months and 4.9, 7.6, and 4 months for smokers, ex-smokers, and non-smokers respectively, without significant differences.</div></div><div><h3>Conclusion</h3><div>In this study, smoking status did not seem to modify the effectiveness of immunotherapy. Studies on a larger population are called for.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 6","pages":"Pages 291-297"},"PeriodicalIF":0.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Les traitements antifibrosants : où en sommes-nous 10 ans après ?","authors":"R. Hindré ,&nbsp;Y. Uzunhan","doi":"10.1016/j.rmr.2025.04.002","DOIUrl":"10.1016/j.rmr.2025.04.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Les pneumopathies interstitielles diffuses (PID) fibrosantes sont des pathologies respiratoires sévères pouvant conduire à l’insuffisance respiratoire et au décès. Au cours des dix dernières années, les traitements antifibrosants ont constitué une avancée thérapeutique majeure et sont désormais largement utilisés.</div></div><div><h3>État des connaissances</h3><div>La pirfenidone et le nintedanib sont indiqués dans le traitement de la fibrose pulmonaire idiopathique (FPI), alors que seul le nintedanib est indiqué dans la PID de sclérodermie systémique et des fibroses pulmonaires progressives (FPP). Ils permettent de diminuer le déclin de la capacité vitale forcée (CVF) pour ces 3 indications et de réduire la mortalité, les exacerbations aiguës, et la détérioration de la qualité de vie au cours de la FPI et des FPP.</div></div><div><h3>Perspectives</h3><div>Un des enjeux majeurs reste la tolérance des traitements amenant à évaluer des modalités de prise différentes comme la voie inhalée. De nombreux essais thérapeutiques sont en cours et des résultats encourageants d’études de phase 3 devraient aboutir à la prescription de nouvelles molécules anti-fibrosantes.</div></div><div><h3>Conclusion</h3><div>Les antifibrosants ont montré leur place importante dans le traitement de la FPI et des FPP. Leur prescription repose sur une décision partagée avec le patient, et peut être proposée précocement et chez des sujets âgés, sous réserve d’un accompagnement dédié.</div></div><div><h3>Introduction</h3><div>Fibrosing interstitial lung diseases (ILD) are severe respiratory conditions that can lead to respiratory failure and death. Over the past decade, antifibrotic therapies have represented a significant therapeutic advancement and are now widely used.</div></div><div><h3>State of the art</h3><div>Pirfenidone and nintedanib have been approved for the treatment of idiopathic pulmonary fibrosis (IPF), while only nintedanib has been approved for systemic sclerosis-related ILD and progressive pulmonary fibrosis (PPF). Both drugs help to reduce the decline in forced vital capacity (FVC) characterizing these three indications and to decrease mortality, acute exacerbations, and quality of life impairment in patients with IPF and PPF.</div></div><div><h3>Perspectives</h3><div>Tolerance to these treatments remains a major challenge, prompting evaluation of alternative administration routes, such as inhalation. Numerous ongoing clinical trials and encouraging results from phase 3 studies are expected to lead to the approval of new antifibrotic molecules.</div></div><div><h3>Conclusions</h3><div>Antifibrotic therapies have proven to be crucial in the management of IPF and PPF. Prescription should be a shared decision with the patient and may be considered at an early stage, even in elderly individuals, provided that dedicated support is avaialble.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 6","pages":"Pages 307-317"},"PeriodicalIF":0.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0761-8425(25)00193-7","DOIUrl":"10.1016/S0761-8425(25)00193-7","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 6","pages":"Page iii"},"PeriodicalIF":0.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}